IRIS Accounts Production v24.1.0.578 08350673 director 1.2.23 31.1.24 31.1.24 false true false false true false Ordinary 1.00000 iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh083506732023-01-31083506732024-01-31083506732023-02-012024-01-31083506732022-06-30083506732022-07-012023-01-31083506732023-01-3108350673ns15:EnglandWales2023-02-012024-01-3108350673ns14:PoundSterling2023-02-012024-01-3108350673ns10:Director12023-02-012024-01-3108350673ns10:PrivateLimitedCompanyLtd2023-02-012024-01-3108350673ns10:SmallEntities2023-02-012024-01-3108350673ns10:AuditExempt-NoAccountantsReport2023-02-012024-01-3108350673ns10:SmallCompaniesRegimeForDirectorsReport2023-02-012024-01-3108350673ns10:SmallCompaniesRegimeForAccounts2023-02-012024-01-3108350673ns10:FullAccounts2023-02-012024-01-3108350673ns10:OrdinaryShareClass12023-02-012024-01-3108350673ns10:CompanySecretary12023-02-012024-01-3108350673ns10:RegisteredOffice2023-02-012024-01-3108350673ns5:CurrentFinancialInstruments2024-01-3108350673ns5:CurrentFinancialInstruments2023-01-3108350673ns5:Non-currentFinancialInstruments2024-01-3108350673ns5:Non-currentFinancialInstruments2023-01-3108350673ns5:ShareCapital2024-01-3108350673ns5:ShareCapital2023-01-3108350673ns5:RetainedEarningsAccumulatedLosses2024-01-3108350673ns5:RetainedEarningsAccumulatedLosses2023-01-3108350673ns5:PlantMachinery2023-02-012024-01-3108350673ns5:PlantMachinery2023-01-3108350673ns5:PlantMachinery2024-01-3108350673ns5:PlantMachinery2023-01-3108350673ns5:CostValuation2024-01-3108350673ns5:CostValuation2023-01-3108350673ns5:AdditionsToInvestments2024-01-3108350673ns5:CurrentFinancialInstrumentsns5:WithinOneYear2024-01-3108350673ns5:CurrentFinancialInstrumentsns5:WithinOneYear2023-01-3108350673ns5:CurrentFinancialInstruments2023-02-012024-01-3108350673ns5:Non-currentFinancialInstrumentsns5:BetweenTwoFiveYears2024-01-3108350673ns5:Non-currentFinancialInstrumentsns5:BetweenTwoFiveYears2023-01-3108350673ns10:OrdinaryShareClass12024-01-31
REGISTERED NUMBER: 08350673 (England and Wales)













Unaudited Financial Statements

For The Year Ended 31 January 2024

for

WAVE PHARMA LIMITED

WAVE PHARMA LIMITED (REGISTERED NUMBER: 08350673)






Contents of the Financial Statements
For The Year Ended 31 January 2024




Page

Company Information 1

Balance Sheet 2

Notes to the Financial Statements 4


WAVE PHARMA LIMITED

Company Information
For The Year Ended 31 January 2024







DIRECTOR: M A Khan





SECRETARY: Mrs R Khan





REGISTERED OFFICE: 79 College Road
Harrow
Middlesex
HA1 1BD





REGISTERED NUMBER: 08350673 (England and Wales)





ACCOUNTANTS: Ayman Tyler Associates
Accountants & Tax Advisers
79 College Road
Harrow
Middlesex
HA1 1BD

WAVE PHARMA LIMITED (REGISTERED NUMBER: 08350673)

Balance Sheet
31 January 2024

31.1.24 31.1.23
Notes £    £    £    £   
FIXED ASSETS
Tangible assets 4 1,644 2,248
Investments 5 269,122 170,122
270,766 172,370

CURRENT ASSETS
Debtors 6 670,224 956,125
Cash at bank and in hand 591,320 62,828
1,261,544 1,018,953
CREDITORS
Amounts falling due within one year 7 1,396,522 1,083,015
NET CURRENT LIABILITIES (134,978 ) (64,062 )
TOTAL ASSETS LESS CURRENT
LIABILITIES

135,788

108,308

CREDITORS
Amounts falling due after more than one
year

8

-

39,085
NET ASSETS 135,788 69,223

CAPITAL AND RESERVES
Called up share capital 10 100 100
Retained earnings 135,688 69,123
SHAREHOLDERS' FUNDS 135,788 69,223

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 January 2024.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 January 2024 in accordance with Section 476 of the Companies Act 2006.

The director acknowledges his responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

WAVE PHARMA LIMITED (REGISTERED NUMBER: 08350673)

Balance Sheet - continued
31 January 2024


The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the director and authorised for issue on 27 March 2024 and were signed by:





M A Khan - Director


WAVE PHARMA LIMITED (REGISTERED NUMBER: 08350673)

Notes to the Financial Statements
For The Year Ended 31 January 2024

1. STATUTORY INFORMATION

WAVE PHARMA LIMITED is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Turnover
Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.
Plant and machinery etc - 33% on cost

Investments in associates
Investments in associate undertakings are recognised at cost.

Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Hire purchase and leasing commitments
Rentals paid under operating leases are charged to profit or loss on a straight line basis over the period of the lease.

Pension costs and other post-retirement benefits
The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 4 (2023 - 1 ) .

WAVE PHARMA LIMITED (REGISTERED NUMBER: 08350673)

Notes to the Financial Statements - continued
For The Year Ended 31 January 2024

4. TANGIBLE FIXED ASSETS
Plant and
machinery
etc
£   
COST
At 1 February 2023 7,907
Additions 1,527
At 31 January 2024 9,434
DEPRECIATION
At 1 February 2023 5,659
Charge for year 2,131
At 31 January 2024 7,790
NET BOOK VALUE
At 31 January 2024 1,644
At 31 January 2023 2,248

5. FIXED ASSET INVESTMENTS

31.1.24 31.1.23
£    £   
Participating interests 65 65
Loans to undertakings in which the company
has a participating interest

269,057

170,057
269,122 170,122

Additional information is as follows:
Interest
in
associate
£   
COST
At 1 February 2023
and 31 January 2024 65
NET BOOK VALUE
At 31 January 2024 65
At 31 January 2023 65

The company's investments at the Balance Sheet date in the share capital of companies include the following:

Associated company

The company had an investment at the balance sheet date in the share capital of Ace Laboratories Ltd, company incorporated in England. Its principal activity is that of Pharmaceuticals quality control testing & research. At the balance sheet date the company held 65 ordinary shares representing a 13% holding.

WAVE PHARMA LIMITED (REGISTERED NUMBER: 08350673)

Notes to the Financial Statements - continued
For The Year Ended 31 January 2024

5. FIXED ASSET INVESTMENTS - continued
Loans to
associates
£   
At 1 February 2023 170,057
New in year 99,000
At 31 January 2024 269,057

6. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
31.1.24 31.1.23
£    £   
Trade debtors 506,959 614,237
Other debtors 163,265 341,888
670,224 956,125

Other Debtors balance includes £100,500 loaned to Eiman Pharma Limited, £30,000 to H S Juttla & £14,365 to Arise Pharma Ltd.

7. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
31.1.24 31.1.23
£    £   
Trade creditors 757,884 589,460
Taxation and social security 188,302 43,024
Other creditors 450,336 450,531
1,396,522 1,083,015

Other Creditors balance includes £1,000 loaned by Wave Pharma Regulatory Ltd, £92,575 by ASA Life PTE, £79,825 by Asia Brothers Group, £218,363 by Baggia Trading PTE & £53,008 by Digital Impex PTE.

8. CREDITORS: AMOUNTS FALLING DUE AFTER MORE THAN ONE
YEAR
31.1.24 31.1.23
£    £   
Bank loans (see note 9) - 39,085

9. LOANS

An analysis of the maturity of loans is given below:

31.1.24 31.1.23
£    £   
Amounts falling due between two and five years:
Bank loans - 2-5 years - 39,085

The company received a 6 year government backed bounce back loan for £50,000 on 6th August 2020 with the option of a Pay As You Grow Variation amendment effective from 4th August 2021.

WAVE PHARMA LIMITED (REGISTERED NUMBER: 08350673)

Notes to the Financial Statements - continued
For The Year Ended 31 January 2024

10. CALLED UP SHARE CAPITAL

Allotted, issued and fully paid:
Number: Class: Nominal 31.1.24 31.1.23
value: £    £   
100 Ordinary £1 100 100

The shareholdings in the company are as follows;

Mohammad Arsalaan Khan 50 Ordinary Shares of £1 each
Romana Khan 50 Ordinary Shares of £1 each